60 Degrees Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$3.45next fiscal year
Monitoring Framework
Key Performance Indicators
Net Product Revenues Annually1M
Net Product Revenues (Q1) Quarterly162.1K
Cash and Cash Equivalents Quarterly3.3M
Watch Items
- Going Concern Risk and Cash RunwayTrigger: Mid-September 2026Action: Secure additional equity/debt financing or business development transactions to extend the cash runway beyond the current projection.
- Interim Analysis of Randomized Hospital Study for BabesiosisTrigger: Late September 2026Action: Monitor patient recruitment patterns during the 2026 tick season to ensure timely data release.
- Nasdaq Minimum Bid Price ComplianceTrigger: Below $1.00 minimum closing bid priceAction: Evaluate the impact of the 1-for-4 reverse stock split executed on January 20, 2026, and prepare for potential further reverse splits (authorized range of 1:5 to 1:10) if non-compliance persists.
Research as of 20 Jun 2026